Major Estimate Revision • May 20
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$137.3m to US$115.2m. Forecast losses increased from -US$0.444 to -US$0.678 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$7.40 to US$3.90. Share price fell 55% to US$0.84 over the past week. Reported Earnings • May 14
Full year 2025 earnings released: US$0.67 loss per share (vs US$1.16 loss in FY 2024) Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Breakeven Date Change • May 14
No longer forecast to breakeven The 6 analysts covering MDxHealth no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.97m in 2028. New consensus forecast suggests the company will make a loss of US$11.3m in 2028. New Risk • May 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$34m Forecast net loss in 3 years: US$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years). New Risk • May 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$96.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$12m). Minor Risk Market cap is less than US$100m (US$96.1m market cap). Reported Earnings • Apr 09
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: US$0.67 loss per share (improved from US$1.16 loss in FY 2024). Revenue: US$107.9m (up 20% from FY 2024). Net loss: US$33.5m (loss narrowed 12% from FY 2024). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Annuncio • Mar 17
MDxHealth SA Highlights Data from Oxford’s Prompt Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings At EAU 2026 Mdxhealth SA announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London. The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford, highlighted how the GPS mdx assay identified patients with biologically indolent prostate cancer despite adverse clinical risk factors. The findings demonstrate how GPS mdx insights help personalize treatment decisions by identifying patients who may safely benefit from treatment de-escalation. The GPS-ProMPT study evaluated 409 patients with localized or locally advanced prostate cancer with a median follow-up of at least six years. Patients in the cohort were managed with active surveillance, radical prostatectomy, or radiotherapy, enabling investigators to assess the predictive performance of the GPS mdx test across multiple treatment pathways. The GPS mdx test successfully stratified the risk of treatment failure across treatment cohorts. Six-year freedom-from-failure outcomes were excellent in these discordant groups, including 92% in Active Surveillance patients and up to 100% among patients treated with surgery or radiotherapy, outcomes that are comparable to concordant low-risk patients. Major Estimate Revision • Mar 06
Consensus EPS estimates fall by 46% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$0.28 to -US$0.41 per share. Revenue forecast unchanged at US$136.6m. Biotechs industry in the US expected to see average net income decline 8.6% next year. Consensus price target of US$7.40 unchanged from last update. Share price fell 3.8% to US$3.27 over the past week. Breakeven Date Change • Mar 02
Forecast breakeven date pushed back to 2028 The 6 analysts covering MDxHealth previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 58% per year to 2027. The company is expected to make a profit of US$3.70m in 2028. Average annual earnings growth of 79% is required to achieve expected profit on schedule. New Risk • Feb 27
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$31m Forecast net loss in 2 years: US$2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.3m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$2.0m net loss in 2 years). Annuncio • Feb 27
MDxHealth SA Maintains Earnings Guidance for the Year 2026 MDxHealth SA maintained earnings guidance for the year 2026. For the year, the company expects revenue guidance of $137 million - $140 million. Breakeven Date Change • Nov 28
Forecast to breakeven in 2027 The 6 analysts covering MDxHealth expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2026. The company is expected to make a profit of US$2.35m in 2027. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Annuncio • Nov 13
MDxHealth SA Provides Earnings Guidance for the Fourth Quarter of 2025 and Reaffirms Earnings Guidance for the Full Year of 2025 MDxHealth SA provided earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects fourth quarter revenue growth to meet or exceed 20%.
Despite the elimination of expected Germline revenue contribution in Third Quarter and Q4, the company remain confident in reaffirming full-year guidance of $108 million to $110 million and expect full year revenue growth to meet or exceed 20%. Annuncio • Sep 16
MDxHealth SA (NasdaqCM:MDXH) acquired Business of Exosome Diagnostics, Inc. MDxHealth SA (NasdaqCM:MDXH) signed a definitive agreement to acquire Business of Exosome Diagnostics, Inc. for $15 million on August 5, 2025. Total consideration for the acquisition is $15 million, with $5 million in stock to be paid at closing and $2.5 million annually over the following 4 years with 50% payable in cash and 50% payable in cash or stock. The transaction is subject to customary closing conditions and is expected to close in September.
XMS Capital Partners acted as financial advisor and K&L Gates acted as legal advisor to MDxHealth for this acquisition, Baker McKenzie served as legal advisor for Belgian corporate matters.
MDxHealth SA (NasdaqCM:MDXH) completed the acquisition of Business of Exosome Diagnostics, Inc. on September 15, 2025. Annuncio • Aug 06
Mdxhealth SA Reaffirms Revenue Guidance for 2025 Mdxhealth SA reaffirmed revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million. Annuncio • May 15
Mdxhealth Sa Reiterates Revenue Guidance for 2025 Mdxhealth Sa reiterated revenue guidance for 2025. For the period, the company expects revenue of $108 million to $110 million. Annuncio • Feb 27
MDxHealth SA Reaffirms Earnings Guidance for the Year 2025 MDxHealth SA reaffirms earnings guidance for the year 2025. The Company is maintaining its previously issued 2025 revenue guidance of $108 million to $110 million. Annuncio • Sep 26
MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million. MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.
Security Name: Ordinary Shares
Security Type: Common Stock Annuncio • May 03
MDxHealth SA Revises Earnings Guidance for the Year 2024 MDxHealth SA revised earnings guidance for the year 2024. For the period, the company is increasing 2024 revenue guidance to $83 million to 85 million from the previous $79 million to 81 million. Annuncio • May 01
MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million. MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Mar 13
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering Mdxhealth SA announced the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.ermline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients. Prostate cancer remains a leading cause of cancer-related death among men, with an estimated 288,300 new diagnoses and 34,700 deaths annually. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of neurological cancers and other urologic diseases. Annuncio • Mar 07
MDxHealth SA Maintains Earnings Guidance for the Year 2024 MDxHealth SA maintained earnings guidance for the year 2024. For the year, the company is maintaining its previously issued 2024 revenue guidance of $79-81 million. Annuncio • Feb 16
MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors MDxHealth SA announced that Jan Pensaert has stepped down from the Board of Directors. His resignation was effective as of February 15, 2024. Mr. Pensaert’s resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Annuncio • Jan 09
MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024 MDxHealth SA provided earnings guidance for the fourth quarter and full year 2023 and year 2024. For the quarter, Company expects revenue of approximately $19.4 million. For the full year 2023, Company expects revenue of approximately $70.2 million. For the year 2024, Company expects revenue $79 million to $81 million. which would represent year-over-year revenue growth of approximately 13%-15%. Annuncio • Nov 29
MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023 MDxHealth SA announced the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") facility (the "Mandatory ADS Exchange"), the start of the transition to a single listing on Nasdaq, and details on the process for repositioning of the Company's shares from the Euronext Brussels trading system to the Nasdaq trading system. The Company announced on October 2, 2023, that its board of directors had determined that it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company's securities on one exchange in the United States. This transaction involves (1) a share consolidation with respect to all outstanding Company shares by means of a 1-for-10 reverse stock split, which was completed on November 13, 2023 (the "Share Consolidation"), after which ten former Company shares are represented by one new Company share (each new Company share, a "Share"), and each ADS represents one new Share, (2) listing the Shares on Nasdaq, (3) the Mandatory ADS Exchange, (4) a repositioning of the Shares from the Euronext Brussels trading system to the Nasdaq trading system, and (5) following a transition period of at least three weeks after the Mandatory ADS Exchange, the de-listing of the Shares from listing and trading on Euronext Brussels. Following the completion of the Share Consolidation on November 13, 2023, the Company completed the Mandatory ADS Exchange, effective November 27, 2023. As a result of the Mandatory ADS Exchange, ADS holders received Shares that are listed on Nasdaq in exchange for their ADSs on the basis of a ratio of one ADS for one Share, the ADS program will be terminated and the ADSs will cease to be listed and traded on Nasdaq. Effective as of the opening of trading on Nasdaq today, the Shares will be admitted to listing and trading on Nasdaq. During a transition period ending December 15, 2023, the Shares will be listed on both Euronext Brussels and Nasdaq. In view of the foregoing, effective as of close of trading on Euronext Brussels on December 15, 2023, the Shares will no longer be listed and traded on Euronext Brussels. As of that moment on, the Shares will only be listed and traded on Nasdaq. Annuncio • Nov 11
MDxHealth SA Provides Earnings Guidance for the Year 2023 MDxHealth SA provided earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million. Annuncio • Nov 10
MDxHealth SA Revises Earnings Guidance for the Year 2023 MDxHealth SA revised earnings guidance for the year 2023. Looking ahead, the company expects strong revenue growth, all leading to its projected turn to operating profitability. With respect to guidance, the company expects to reach the high end of its 2023 revenue guidance of $65 million - $70 million. Annuncio • Oct 05
MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023 MDxHealth SA announced that they will report Q3, 2023 results at 5:40 PM, Central European Standard Time on Oct 09, 2023 Annuncio • Aug 24
MDxHealth SA Reaffirms Revenue Guidance for the Year 2023 MDxHealth SA announced that the company reaffirms full year 2023 revenue guidance of $65 million - $70 million. 
